Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabazitaxel

FDA-approved product (solution, intravenous), marketed as Cabazitaxel, Jevtana Kit.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cabazitaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma
  • Prostate neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabazitaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabazitaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

    NCT06738303 · start 2025-07-14

    Registered record
    Registry ID
    NCT06738303
    Conditions
    Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
    Interventions
    Cabazitaxel and carboplatin; Lu-PSMA-617
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-14
    Completion
    2026-12
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
    InterventionCabazitaxel and carboplatin; Lu-PSMA-617
    PhasePhase 2
    Registry statusRecruiting

  • Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

    NCT06632977 · start 2025-02-06

    Registered record
    Registry ID
    NCT06632977
    Conditions
    Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Genetic testing; Valemetostat Tosylate; Magnetic Resonance Imaging; Computed Tomography; Bone scan; FDG-Positron Emission Tomography; PSMA PET Scan; Biospecimen Collection; Carboplatin; Cabazitaxel; Abiraterone Acetate; Enzalutamide; Lutetium Lu 177 Vipivotide Tetraxetan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-02-06
    Completion
    2034-10-11
    Enrolment
    474

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionGenetic testing; Valemetostat Tosylate; Magnetic Resonance Imaging; Computed Tomography +9 more
    PhasePhase 2
    Registry statusRecruiting

  • Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

    NCT06470243 · start 2024-11-27

    Registered record
    Registry ID
    NCT06470243
    Conditions
    Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Biospecimen Collection; Bone Scan; Cabazitaxel; Carboplatin; Chest Radiography; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-11-27
    Completion
    2034-04
    Enrolment
    528

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionBiospecimen Collection; Bone Scan; Cabazitaxel; Carboplatin +5 more
    PhasePhase 3
    Registry statusRecruiting

  • A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

    NCT07477756 · start 2024-09-04

    Registered record
    Registry ID
    NCT07477756
    Conditions
    Prostate Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-09-04
    Completion
    2025-03-14
    Enrolment
    1,247

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

    NCT06353386 · start 2024-05-20

    Registered record
    Registry ID
    NCT06353386
    Conditions
    Prostatic Neoplasms, Castration-Resistant
    Interventions
    Opevesostat; Olaparib; Docetaxel; Cabazitaxel; Fludrocortisone acetate; Dexamethasone; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-05-20
    Completion
    2029-01-15
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms, Castration-Resistant
    InterventionOpevesostat; Olaparib; Docetaxel; Cabazitaxel +3 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

    NCT05563558 · start 2023-05-05

    Registered record
    Registry ID
    NCT05563558
    Conditions
    Prostate Cancer Metastatic
    Interventions
    Pembrolizumab; Carboplatin; Cabazitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-05-05
    Completion
    2026-11-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionPembrolizumab; Carboplatin; Cabazitaxel
    PhasePhase 2
    Registry statusRecruiting

  • Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

    NCT05701007 · start 2023-02-13

    Registered record
    Registry ID
    NCT05701007
    Conditions
    Metastatic Castration Sensitive Prostate Cancer (mCSPC); Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Interventions
    abiraterone; enzalutamide; docetaxel; apalutamide; cabazitaxel; Radium-223; Lutetium-177; degarelix; goserelin; leuprorelin; triptorelin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-02-13
    Completion
    2024-04-10
    Enrolment
    1,083

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration Sensitive Prostate Cancer (mCSPC); Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Interventionabiraterone; enzalutamide; docetaxel; apalutamide +7 more
    PhaseNot recorded
    Registry statusCompleted

  • XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

    NCT05005728 · start 2021-10-22

    Registered record
    Registry ID
    NCT05005728
    Conditions
    Metastatic Castration-Resistant Prostate Cancer
    Interventions
    vudalimab + carboplatin + cabazitaxel; vudalimab + olaparib; vudalimab monotherapy; vudalimab + docetaxel; vudalimab + cabazitaxel or docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-10-22
    Completion
    2025-06-10
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostate Cancer
    Interventionvudalimab + carboplatin + cabazitaxel; vudalimab + olaparib; vudalimab monotherapy; vudalimab + docetaxel +1 more
    PhasePhase 2
    Registry statusCompleted

  • Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

    NCT04337580 · start 2021-03-05

    Registered record
    Registry ID
    NCT04337580
    Conditions
    Prostate Cancer; Refractory Cancer; Castration Resistant Prostatic Cancer
    Interventions
    Omeprazole 80 mg twice daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-03-05
    Completion
    2028-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Refractory Cancer; Castration Resistant Prostatic Cancer
    InterventionOmeprazole 80 mg twice daily
    PhasePhase 2
    Registry statusRecruiting

  • PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn

    NCT04256993 · start 2020-02-15

    Registered record
    Registry ID
    NCT04256993
    Conditions
    Metastatic Castration-Resistant Prostate Cancer
    Interventions
    Radium-223 dichloride (Xofigo, BAY88-8223); Other standard care
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-02-15
    Completion
    2021-06-01
    Enrolment
    1,434

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostate Cancer
    InterventionRadium-223 dichloride (Xofigo, BAY88-8223); Other standard care
    PhaseNot recorded
    Registry statusCompleted

  • Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide

    NCT03764540 · start 2019-04-01

    Registered record
    Registry ID
    NCT03764540
    Conditions
    Metastatic Prostate Cancer
    Interventions
    Cabazitaxel plus prednisone; Docetaxel plus prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-04-01
    Completion
    2024-12-31
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    InterventionCabazitaxel plus prednisone; Docetaxel plus prednisone
    PhasePhase 2
    Registry statusTerminated

  • Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic

    NCT03101046 · start 2018-11-15

    Registered record
    Registry ID
    NCT03101046
    Conditions
    Prostate Carcinoma; Castration-resistant Prostate Cancer; Circulating Tumor Cells; Chemotherapy
    Interventions
    Cabazitaxel; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-11-15
    Completion
    2021-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Carcinoma; Castration-resistant Prostate Cancer; Circulating Tumor Cells; Chemotherapy
    InterventionCabazitaxel; Docetaxel
    PhasePhase 2
    Registry statusCompleted

  • Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

    NCT03263650 · start 2017-10-03

    Registered record
    Registry ID
    NCT03263650
    Conditions
    Prostate Cancer Aggressiveness; Prostate Carcinoma
    Interventions
    Cabazitaxel; Carboplatin; Prednisone 5Mg; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-10-03
    Completion
    2026-06-10
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Aggressiveness; Prostate Carcinoma
    InterventionCabazitaxel; Carboplatin; Prednisone 5Mg; Olaparib
    PhasePhase 2
    Registry statusCompleted

  • Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

    NCT02961257 · start 2017-05-05

    Registered record
    Registry ID
    NCT02961257
    Conditions
    Prostate Cancer Metastatic
    Interventions
    cabazitaxel; Prednisone; Granulocyte colony-stimulating factor (G-CSF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-05-05
    Completion
    2021-12-02
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    Interventioncabazitaxel; Prednisone; Granulocyte colony-stimulating factor (G-CSF)
    PhasePhase 3
    Registry statusCompleted

  • Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

    NCT03043989 · start 2017-03-21

    Registered record
    Registry ID
    NCT03043989
    Conditions
    Prostate Cancer
    Interventions
    Docetaxel; Cabazitaxel; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2017-03-21
    Completion
    2019-07-26
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDocetaxel; Cabazitaxel; Clarithromycin
    PhasePhase 1
    Registry statusTerminated